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Abstract  
 
Transcriptional reprogramming of proliferative melanoma cells into a phenotypically distinct 
invasive cell subpopulation is a critical event at the origin of metastatic spreading. Here we 
generate transcriptome, open chromatin and histone modification maps of melanoma cultures 
and integrate our data with existing transcriptome and DNA methylation profiles from tumor 
biopsies to gain insight into the mechanisms underlying this key reprogramming event. This 
shows thousands of genomic regulatory regions underlying the proliferative and invasive state, 
identifying SOX10/MITF and AP-1/TEAD as regulators respectively. Knock-down of TEADs 
shows a previously unrecognized role in the invasive gene network and establishes a causative 
link between these transcription factors, cell invasion and sensitivity to MAPK inhibitors. Using 
regulatory landscapes and in silico analysis, we show that transcriptional reprogramming 
underlies the distinct cellular states present in melanoma. Furthermore it reveals an essential role 
for the TEADs, linking it to clinically relevant mechanisms such as invasion and resistance.   
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Introduction 
 
Melanoma is one of the most aggressive cancers and although investigation into the genetic 
underpinnings of melanoma have led to promising therapeutics, clinical outcome remains poor, 
with most patients rapidly acquiring resistance1. The difficulty in eradicating melanoma lies in its 
high degree of heterogeneity and plasticity. Melanoma comprises multiple phenotypically 
distinct subpopulations of cancer cells, all with a potentially variable sensitivity to therapy2. 
However, the mechanisms evoking this heterogeneity are largely uncharacterized. 
Gene expression profiling of cultured melanoma cell lines3–5 identified two types of cultures 
characterized by very distinct transcriptomes. Samples of the “proliferative” type express high 
levels of the melanocyte-lineage specific transcription factor MITF6 as well as SOX10 and 
PAX37,8. In contrast, samples of the “invasive” type express low levels of MITF, high levels of 
the Epithelial-to-Mesenchymal Transition (EMT)-related transcription factor (TF) ZEB15,9 and 
genes involved in TGF-ß signaling. It has been proposed that melanoma invasion is triggered by 
the appearance of clusters of MITF-low/ZEB1-high cells at the edge of the primary lesions5. 
These cells acquire migratory properties allowing them to invade the dermis, enter the blood 
stream and eventually contribute to metastatic dissemination. Interestingly, MITF-positive cells 
are also found at metastatic sites, suggesting an ability of melanoma cells to switch back and 
forth between these transcriptional states. While several models have been proposed to explain 
these observations, the initial event always involves a transition in the primary tumor from a 
proliferative to an invasive cell state. This (reversible) transition is likely caused by dynamic 
transcriptional changes driven by differential chromatin architecture, and changes in the activity 
of master regulators and gene regulatory networks4,10. In support of this, no “metastasis-driving” 
mutations have thus far been found in primary and metastatic tumors from the same patient.  
Importantly, it has been proposed that distinct transcriptional cell states characterized by variable 
MITF or SOX10 activity influence resistance to MAPK pathway inhibitors1,11 . Interestingly, 
enforcing MITF expression “pushes” cells towards a different cell state12 which could then be 
exploited therapeutically. This illustrates how a better understanding of the molecular processes 
underlying the proliferative-to-invasive transition can be used to overcome drug resistance and 
improve current therapies. As these processes are largely driven by changes in gene regulatory 
networks, new insight may be gained by genome-wide mapping and decoding of the chromatin 
landscapes and the master regulators that control the distinct transcriptomic states in melanoma. 
In this study we first provide evidence that the cell states described in vitro are also recapitulated 
in microarray and RNA-seq data sets across tumor biopsies. Next, we map the transcriptome and 
chromatin landscape of ten short-term melanoma cultures and find thousands of genomic 
regulatory regions underlying the proliferative and invasive state. Using an integrated approach 
for motif and track discovery we confirm SOX10/MITF as master regulators of the proliferative 
gene network and identify AP-1/TEAD as new master regulators of the invasive gene network. 
We experimentally validate chromatin interactions upstream of SOX9 by 4C-seq, and we test the 
TEAD predicted network using knock-down experiments. These experiments establish a 
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previously unrecognized role for the TEADs in the invasive gene network and reveal a causative 
link between these TFs, cell invasion and sensitivity to MAPK inhibitors. 
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Results  
 
Proliferative and invasive gene signatures in tumor samples 
The invasive and proliferative transcriptional cell states have thus far only been described in 
vitro. We asked whether the transcriptome of these two distinct cell populations could be 
observed in clinical samples. To this end, we assembled three compendia of publicly available 
melanoma gene expression data (Supplementary Table 1). Unsupervised clustering revealed 
that each of the three compendia clustered into three similar-sized clusters, two exhibiting 
features reminiscent of the proliferative and invasive cell states and a third exhibiting an 
immune-related signature presumably due to the presence of a high number of tumor-infiltrating 
lymphocytes (TIL) (Fig. 1a-b and Supplementary Fig. 1, 2). Accordingly, the gene signatures 
derived for both the proliferative and invasive cluster show very significant overlap with the 
Hoek3 gene signatures representing curated gene lists for proliferative and invasive melanoma 
states in culture (Supplementary Fig. 3a). As expected, samples in the invasive cluster have 
high expression of genes identified as miR-200 targets or implicated in TGF-ß and JNK 
signaling, cell migration, stemness and EMT (Fig. 1b). Genes that are up-regulated in this cluster 
include ZEB1, SNAI1 and TGFB2. In contrast, genes with high expression in the proliferative 
sample cluster are significantly enriched for cell cycle, proliferation, and melanocytic processes. 
Genes up-regulated in this cluster include known markers of the melanocyte lineage and 
melanoma such as SOX10, MITF and PAX3 (Supplementary Fig. 3b). Consistently, when the 
entire gene expression pattern of a sample is visualized using Self-Organizing Maps (SOMs)13 
some of the invasive and proliferative samples show remarkable similarities (Fig. 1c, 
Supplementary Note 2). In addition, these transcriptomes are highly similar to the 
transcriptomes of the previously defined invasive and proliferative melanoma cultures. These 
observations indicate that the clinical samples cluster into distinct groups and that these represent 
cellular subpopulations in either the proliferative or the invasive cell state. However, whether 
mutations or transcriptional reprogramming forms the driver of these subpopulations is a matter 
of debate. Our analysis of the exome re-sequencing data from the same TCGA cohort did not 
identify specific enrichments for mutations in BRAF, NRAS or any of the other well-established 
melanoma driver genes (n=116) in either of the clusters (Supplementary Note 1). This 
observation favors the possibility that these very distinct cell states are driven largely by 
transcriptional reprogramming rather than by common genetic mutations.  
Together these data indicate that, despite the fact that all of these samples originate from 
different human patients with very divergent mutational profiles, most tumors fall into one of 
these two dominant states. Note that when analyzing the immune infiltrated cluster separately, 
the samples also show a tendency towards either of these two states, suggesting that the immune 
signature may, at least partly, represent a layer that confounds the underlying melanoma states 
(Supplementary Fig. 4).  
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Changes in the chromatin landscape underlie cellular states 
The above findings support in vitro short-term cultures as valid model system that can be 
exploited to decipher the chromatin landscapes and regulatory networks underlying these two 
transcriptional cell states. Therefore, we profiled the transcriptome and chromatin landscape of 
ten short-passage melanoma cultures previously described14 and one classical melanoma cell line 
(SK-MEL-5; see accession code for data availability15). The transcriptome of all eleven samples 
was compared to publicly available gene expression data from melanoma cultures and to the 
clusters of tumor biopsies described above using SOMs (Fig. 1c). This comparison indicated that 
cultures MM047 and MM099 are in an invasive transcriptional state while the remaining harbor 
a transcriptome reminiscent of the proliferative state (Supplementary Table 2). This 
correspondence was further supported by a significant enrichment of the invasive and 
proliferative gene signatures from Hoek et al., and by the high expression of invasive marker 
genes such as ZEB1, SOX9 and WNT5A (Supplementary Fig. 3, 5-6). In contrast, these samples 
have undetectable SOX10 and MITF while the other nine samples express high SOX10 and MITF 
levels (Fig. 2, Supplementary Fig. 3a, 7). Using these data we established a new gene signature 
for each state, consisting of 772 and 643 genes for the proliferative and invasive phenotype, 
respectively (Supplementary Data 1). Comparing our data with the Hoek gene signatures3,16 
identified 100% of Hoek’s proliferative genes up-regulated in our proliferative samples, while 
100% of Hoek’s invasive genes are up-regulated in our invasive samples (Supplementary Fig. 
3a). Importantly, the cells with an invasive transcriptional profile do exhibit enhanced 
capabilities to invade in a Matrigel® assay compared to the cell lines with a transcriptional 
proliferative state (Supplementary Fig. 8). Additionally, similar to the results obtained using the 
TCGA cohort, the proliferative versus invasive split is not correlated with any specific mutations 
in known melanoma driver genes, such as BRAF (Supplementary Fig. 9). Again, this is 
consistent with the view that acquisition of the invasive cell state is likely to be a consequence of 
transcriptional reprogramming rather than driven by any specific genetic alterations.  
The two expression profiles we identified likely arise through gene regulation by cis-regulatory 
modules. Therefore, we next investigated active cis-regulatory regions underlying the invasive 
and proliferative transcriptional states using open chromatin profiling (FAIRE-seq17) and ChIP-
seq against two important histone modifications representing activated (H3K27Ac) and repressed 
(H3K27me3) chromatin marks. Interestingly, the invasive samples are clustered separately based 
on their chromatin activity profiles, similarly to the clustering based on RNA-seq data. For 
example, the H3K27ac and FAIRE-seq tracks indicate a respectively active and open SOX10 
promoter in the nine proliferative samples with high SOX10 expression. In contrast, the SOX10 
promoter lacks activating marks, but carries repressing H3K27me3 marks in the two invasive 
cultures (Fig. 2). This reciprocity is a genome-wide property since the two invasive samples 
clearly segregate from the other samples in a multidimensional scaling unsupervised analysis 
(MDS) of the H3K27Ac or FAIRE-seq peaks (but not H3K27me3) (Fig. 3a). An overview of the 
entire chromatin landscape, using SOMs based on 55919 genomic enhancers and promoters, 
indicates that the difference between the two cellular states is widespread and involves thousands 
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of regulatory regions (Fig. 3b, Supplementary Note 2). Using two complementary 
computational approaches we predicted 13453 and 6669 regions to have a regulatory role in the 
invasive and proliferative states, respectively (Supplementary Fig. 10, see Methods). 
Interestingly, when comparing enhancers active in the proliferative transcriptional state to 110 
different sets of tissue-specific enhancers identified by the expression of enhancer-RNA (eRNA) 
18, melanocyte is identified as the cell type with the highest overlap of enhancers. In contrast the 
invasive melanoma enhancers overlap most strongly with enhancers specifically active in skin 
fibroblasts, which are known to harbor a mesenchymal regulatory program (Supplementary 
Table 3).  
 
Next we investigated whether there is a global correlation between active chromatin and gene 
expression. Although the assignment of active promoters and enhancers to candidate target genes 
is not a trivial task, an analysis of (differential) H3K27Ac, FAIRE, and H3K27me3 peaks around 
the transcription start site (TSS) of their nearest differentially expressed genes (<20kb around 
TSS) indicates a strong correlation between both layers (Fig. 3c-d, Supplementary Fig. 11). 
Particularly, the TSS of invasive genes shows strong regulatory activity in the invasive samples, 
but low activity in the proliferative samples while the repressive H3K27me3 mark shows the 
opposite (Fig. 3e, Supplementary Fig. 12). These data confirm that these specific chromatin 
marks are robust predictors of the transcriptional activity in a specific cellular state.  
We then asked whether the invasive and proliferative chromatin landscapes are also reflected in 
in vivo tumor biopsies. Hence, we used both the RNA-seq and DNA methylation data from 
TCGA. The TSSs of the differentially expressed genes between invasive and proliferative 
sample clusters are correlated with active chromatin in the corresponding in-house samples 
(Supplementary Fig. 13). Remarkably, differentially methylated regions (DMRs) between the 
invasive and proliferative clinical samples are correlated as well with both gene expression and 
active and repressed chromatin in the melanoma in-house samples (Supplementary Fig. 14-15). 
Particularly, regions that are significantly hypo-methylated in the proliferative group (i.e., likely 
active in the tumor) are also activated (H3K27Ac and FAIRE) in the proliferative cultures, but 
not in the invasive cultures (Fig. 3f). Likewise, enhancers that are only active in the invasive 
cultures are significantly hypo-methylated in the invasive clinical samples (Supplementary Fig. 
16). These findings show that the regulatory landscape can reflect transcriptional program 
changes, thus forming an interesting basis to search for causal TFs driving these distinct 
regulatory programs. 
 
Sequence analysis and ChIP reveal regulators for each state 
Having identified differentially active regulatory regions and differentially expressed genes 
between the invasive and proliferative states, we searched for TFs contributing to the chromatin 
and transcriptional cell state distinction. We employed a large collection of public data sets to 
search for TFs of which the DNA binding motif and/or ChIP-seq tracks significantly overlap 
with active regulatory regions (see Methods). Within the 6669 regulatory regions activated in the 
  7
proliferative cell state, the SOX10 motif is the most significantly enriched and is predicted to 
target 2437 of these regions (36.5%) (Fig. 4a, Supplementary Fig. 17a). Moreover, one of its 
highest scoring target enhancers (position 292 out of 1223024 regions in the genome) is located 
immediately upstream of the SOX10 gene itself, confirming earlier observations that SOX10 is 
autoregulatory19. Another SOX10-candidate target region (ranked 4089) is located upstream of 
the MITF locus, confirming the possibility that SOX10 directly regulates MITF20.  
The second most enriched motif is an E-box motif with 1520 predicted target regions (22.8%). 
Since MITF binds DNA through E-boxes we assessed whether these enhancers represent bona 
fide MITF target sites. The first ranked ChIP-seq track found is one against an over-expressed 
HA-tagged MITF21, indicating a highly significant correlation between the E-box/MITF 
predictions and the ChIP-seq data (hypergeometric adjusted p-value < 1.0e-05, NES = 31.2). 
This analysis enabled us to define an optimal set of direct MITF targets having both the motif 
and a ChIP-seq peak, and contains 776 regulatory regions (Fig. 4b, Supplementary Fig. 17). 
Interestingly, one of the predicted MITF binding sites is located upstream the SOX10 gene, 
indicating the existence of a direct cross-activation between MITF and SOX10. Additionally, we 
performed a ChIP-seq experiment against endogenous MITF in two of the proliferative cell lines 
(MM011 and MM031), confirming that MITF ChIP peaks are enriched among the predicted E-
box enhancers, and that the SOX10 gene is likely a direct target of MITF (Fig. 4c, 
Supplementary Fig. 17).  
The above results confirm that our approach for inferring master regulators using the regulatory 
landscape is valid as it identified the known master regulators of the proliferative state. Therefore 
we repeated this analysis for the 13453 regulatory regions activated in the invasive cell state, 
since no pronounced master regulators have been postulated for this state. Interestingly, the AP-1 
motif is most significantly enriched, being present in 4354 (32%) active regulatory regions (Fig. 
4d and Supplementary Fig. 18). To validate these predictions we performed track discovery and 
found as firstly ranked track the ChIP-seq of FOSL2, an AP1 family member, obtained from the 
neuroblastoma SK-N-SH cell line, strongly indicating that the predicted regions are bona fide 
AP-1 binding sites (Fig. 4e). Even more intriguing is the detection of the DNA-binding motifs of 
the TEAD factors, known effectors of the Hippo signaling pathway22, as the second most 
enriched motif cluster in the invasive cell state (Supplementary Fig. 18). Eleven variants of the 
TEAD motifs are enriched, together yielding 1501 (11%) predicted TEAD target regions 
transcriptionally active in the invasive state (Fig. 4d and Supplementary Fig. 18). Importantly, 
we confirmed that these regulatory regions are likely direct TEAD-targets as they are strongly 
enriched for TEAD ChIP peaks; in particular, TEAD4 ChIP-seq tracks from SK-N-SH and A549 
cell lines ranked first (Fig. 4f).  
In conclusion, these analyses allowed the identification of transcription factors that regulate a 
large number of promoters and enhancers, thereby shedding light on how transcriptional 
reprogramming can distinguish two distinct melanoma cell states. Most intriguing is the fact that 
our data allows us to concretely put forward two putative candidate master regulators for the 
invasive state. 
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Mapping and validating the proliferative and invasive networks 
Deciphering functional gene regulatory networks underlying cellular states requires an 
integration, or “projection” of the cis-regulatory landscape onto the differentially expressed 
genes of each state to identify potential target genes of the enhancers. By connecting the master 
regulators to functional target genes, via the active regulatory regions, a functional network can 
be inferred. Consequently, we predicted genome-wide enhancer-target gene interactions for 
MITF, SOX10, TEAD, and AP-1. Most studies limit enhancer-to-gene mappings to a relatively 
small intergenic space around each gene. By limiting this analysis to 20kb around the TSS, only 
1404 (7%) enhancers can be assigned to genes. This is because enhancer-promoter interactions 
can occur over distances of up-to a few mega base pairs by looping23. To associate distal 
enhancers to their candidate target genes, we tested various parameter settings (Fig. 5a, see 
Methods) linking 4599 enhancers (23%) to 1477 target genes and thus yielding a large gene 
regulatory network for each state (Fig. 5b, Supplementary Data 2). To assess the quality of the 
target gene predictions, and to compare different assignment procedures, we used two rounds of 
validation with public data. In the primary validation round, we tested whether the assigned 
target genes are overall co-expressed with their respective regulator across the TCGA data set, 
whereby co-expression values were calculated using GENIE324 (Fig. 5c, Supplementary Fig. 
19). Particularly, this network inference method yielded a ranked list of downstream targets of 
SOX10 and JUND based on (linear and non-linear) co-expression in the TCGA data. As shown 
in Figure 5c, the predicted direct targets of SOX10 and AP-1 in the network are significantly 
enriched in the top of this co-expression ranking (FDR < 1E-5 by GSEA). Therefore, this 
analysis demonstrates the usefulness of including distal assignments in addition to the proximal 
assignments; and that assignments to the closest correlated gene are better than assignments to 
the closest gene without using any information on the expression of that gene.  
In a secondary validation round, we used publicly available genetic perturbation data for each of 
the predicted master regulators to examine whether the predicted targets are functionally 
dependent or downstream of their regulator8,21,25,26. For each of the four TFs, we found a 
significant overlap between the target gene predictions and the genes expressed downstream of 
the corresponding TF after perturbation, again using ranked gene lists and GSEA analysis (Fig. 
5c). These results validate our predictions and indicate that these targets are likely to be 
functionally important. Interestingly, the invasive network shows a very high and significant 
overlap between the TEAD and AP-1 target genes (Fig 5b) indicating that the regulatory 
function of TEAD is strongly related to AP-1 function in this particular context. This finding is 
corroborated by a high degree of overlap (r =0.38 with p-value < 2.2 e-16) between JUND and 
TEAD4 ChIP-seq peaks in the SK-N-SH neuroblastoma cell line (Fig 6a). Together, these data 
indicate that TEAD may bind cooperatively with AP-1 to regulate its target genes. In conclusion, 
in silico exploitation of epigenomic data allowed us to infer master regulators for each melanoma 
cellular state and identify many downstream targets, without discarding distal regulatory regions. 
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The networks thus created are likely to represent an important part of the global gene regulatory 
network underlying melanoma cell state distinction.  
 
4C-seq shows long-range interactions at the SOX9 locus 
The inferred gene regulatory networks are based on predictions of long-range enhancer-promoter 
interactions to associate distal enhancers to candidate target genes. These predictions are derived 
from correlations between enhancer activity profiles and gene expression profiles. To test 
whether such associations indeed reflect true 3D chromatin interactions, we focused on one 
particularly relevant target gene of the invasive network, SOX9 (Fig. 6) and performed 
Circularized Chromosome Conformation Capture sequencing (4C-seq)27. SOX9 is a TF 
specifically expressed in the invasive state and is mostly known for its involvement in early 
neural crest development28. Additionally, SOX9 has previously been implicated in invasive 
growth in other cancer types such as prostate cancer29. The SOX9 locus contains a very large 
intergenic region of about 2 Mb upstream of the promoter region. We identified 31 significantly 
active regulatory regions -clustered into eight sub-regions- within 1.4 Mb around SOX9 (Fig. 
6a). Each of these distal enhancers is positively correlated with both the activity of the SOX9 
promoter and its expression levels across the 11 melanoma in-house samples indicating that the 
distal elements may indeed interact with the SOX9 promoter and regulate SOX9 transcription. To 
further test this we performed 4C-seq on both MM047 and MM011 using the promoter as well as 
a 1Mb upstream enhancer as viewpoints (Fig. 6b-c). A large number of interactions can be 
observed in the SOX9-positive and invasive MM047, but not in the SOX9-negative MM011. 
Interestingly, 35/44 (79.5%) of all interactions identified are found upstream, showing a strong 
bias towards the upstream region. Remarkably, no specific interactions between distal enhancers 
and the promoter can be observed in MM011, a strong indicator that these interactions can drive 
SOX9 activation. Thus, these results indicate that multiple distal enhancers can interact with a 
single promoter, and that (long-range) chromatin interactions can differ between melanoma 
cellular states. This also shows that correlations between enhancers and genes can be used to 
predict enhancer-promoter interactions, as previously shown for DNAseI Hypersensitivity sites 
and chromatin marks30,31. 
 
TEADs are key regulators of the invasive state and phenotype  
The four TEADs in the human genome have all been implicated as key effectors of the Hippo 
pathway; a pathway previously shown to confer invasive properties to various cancers including 
breast32, esophageal33 and more recently melanoma34. Note however that the implication of the 
Hippo pathway in melanoma was linked to the Hippo transducers YAP and TAZ, which exhibit 
multiple TEAD-independent functions amongst which modifying TGF-ß and WNT 
signaling35,36. In contrast, by using in silico tools and public datasets we raise the possibility that 
the TEADs are directly involved -as master regulators- in the invasive melanoma cell state. For 
example, we find multiple invasive-specific H3K27Ac peaks with predicted TEAD motifs that 
overlap with TEAD ChIP-seq data from ENCODE, in the neighborhood of invasive genes 
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(Supplementary Fig. 20). To test whether these predictions indeed point to functional targets we 
knocked-down (KD) all TEADs simultaneously and asked whether our predicted TEAD target 
genes are affected by this perturbation. The transcriptome of MM047 upon TEADs KD was 
established by RNA-seq and showed significantly decreased levels of all TEADs (3.8 – 7.1 fold) 
(Supplementary Fig. 21). Importantly, a significant subset of all predicted TEAD target genes 
were down-regulated including SOX9, SERPINE, EHPA2 and several Hippo pathway genes (Fig. 
7a-b,d and Supplementary Fig. 22). Interestingly, many of the TEAD-regulated genes have 
already been linked to cell migration, invasion, or metastasis, where their involvement in these 
processes are often experimentally validated either in melanoma or in other cancer types37,38 
(Fig. 7b and Supplementary Data 3, 4). Accordingly, “locomotion” is the most over-
represented Gene Ontology term among the set of predicted TEAD targets (GO:0040011, adj. p-
value 8.05e-26).  
After screening a new series of short-term melanoma cultures by assessing 18 selected genes, we 
identified an additional invasive culture (MM029) and confirmed that it also exhibits a high 
invasive propensity (Supplementary Fig. 23). Importantly, the expression of SOX9, SERPINE1 
and EPHA2 was also decreased upon TEADs KD in these cells (Fig. 7a). Interestingly, KD of 
individual TEAD members indicates that TEADs function in a redundant manner and that the 
complete TEAD transcriptional network shown in Figure 5 likely depends upon the joint activity 
of several or possibly all four TEAD members (Fig. 7a, Supplementary Fig. 24, 25). 
To establish a functional link between TEADs and melanoma cell invasion we knocked-down all 
TEADs simultaneously in eight melanoma cell cultures and measured invasive capacity and cell 
viability. Strikingly, a significant decrease of all three invasive cultures (MM047, MM099, and 
MM029) was observed upon TEADs KD (Fig. 7e-g).  
Collectively these experiments indicate that the TEADs contribute to the establishment of the 
invasive transcriptional cell state and its associated cellular phenotype. These data also underline 
the ability of the TEADs to promote a survival advantage to the melanoma invasive cells.  
 
TEADs sensitize invasive cells to MAPK-targeted therapy 
The therapeutic relevance of the two-class distinction in melanoma was recently highlighted by 
the observation that the two cell states are associated with differential susceptibility to MAPK 
pathway inhibition11,40. To test whether this drug resistance likewise correlates with high 
expression of the TEAD targets we examined the Cancer Cell Line Encyclopedia (CCLE)41. 
Interestingly, there is a significant positive correlation (0.82 with p-value < 1e-5) between 
expression of the TEAD-target gene signature and BRAF-inhibitor (PLX4032) response in 29 
BRAFV600E-mutant cell lines. A similar trend, albeit with a lower correlation coefficient of 0.60 
(p-value < 1e-5), is also observed for resistance to the MEK-inhibitor AZD6244 (n=39) (Fig. 8a 
and Supplementary Fig. 26). These results suggest that TEAD-mediated transcription is one of 
the determinants that contribute to the increased resistance of the invasive melanoma cells to 
MAPK pathway inhibition.  
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To further confirm such a correlation experimentally, we established the IC50 values for both a 
BRAF- and a MEK-inhibitor (PLX4032 and Pimasertib) in several of the short-term cultures. 
Strikingly, invasive cultures are significantly more resistant to these inhibitors than proliferative 
cultures (Fig. 8b). Furthermore, simultaneous KD of all four TEADs significantly (re)sensitizes 
the invasive cultures to the MEK inhibitor (Fig. 8c, Supplementary Fig. 27).  
Together, these results indicate that the TEADs transcriptional network – selectively induced in 
melanoma cells adopting an invasive cell state- confer intrinsic resistance to MAPK-therapeutics.  
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Discussion 
 
Cell state transition in vivo is likely to be driven by changes in the microenvironment, ultimately 
leading to transcriptional reprogramming42. The plasticity and reversibility of phenotype 
switching indeed favors a model in which cell state transition is dependent upon reprogramming 
of the transcriptome rather than dictated by the acquisition of specific DNA mutations. In 
agreement, we found no enrichment for specific gene mutations in the invasive or proliferative 
clinical samples (TCGA). Unexpectedly, when analyzing copy number alterations in the TCGA 
cohort a 7q34 duplication was found to be enriched in the invasive samples. This region harbors 
89 genes and includes the BRAF gene (Supplementary Note 1). Interestingly, over-expression 
of BRAF was recently shown to drive a rapid and reversible switch in a specific subset of 
invasive-related TFs5. Together these data raise the possibility that although melanoma 
phenotype switching is, by and large, governed through transcriptional reprogramming, specific 
genetic lesions may render melanoma cells susceptible to such reprogramming. 
 
The gene expression patterns that define this transcriptional reprogramming have been defined to 
some extent by Hoek and colleagues as a gene signature of 97 genes; 45 specifically expressed in 
invasive and 52 in proliferative cells3. We have extended this gene signature to better capture the 
entire repertoire of genes involved in both states and identified 643 and 772 genes that are up-
regulated in invasive and proliferative cells, respectively. Additionally, we have included (poly-
adenylated) lncRNAs in the analysis by using the GENCODE annotation, classifying 17 into the 
invasive and 49 into the proliferative signature (Supplementary Data 1).  
At a first level, our data allowed us to generate a more extended view of the transcriptional 
reprogramming underlying melanoma cell state transition. However, incorporating regulatory 
profiling and performing profound in silico analyses allowed us to go a step further and identify 
potential regulators behind this reprogramming. Particularly, by decoding the sequences of the 
differentially active regulatory regions, we identified SOX10 and MITF as master regulators of 
the melanoma proliferative cell state. MITF has been extensively studied in the context of 
normal melanocyte development, where it is expressed downstream of PAX3 and SOX107. 
Additionally, it has been shown that MITF is often amplified and over-expressed in 
melanomas43. The MITF target prediction we present herein combines information on active 
genomic regions based on H3K27Ac profiles with active gene expression, and includes distal 
enhancer-promoter interactions. Comparing our results to MITF KD data indicated that our 
MITF target gene prediction is more accurate than those based on ChIP-seq or microarray data 
alone, and includes hundreds of previously unknown MITF targets (Supplementary Fig. 28). 
The second proliferative master regulator is SOX10, a key regulator of neural crest cell 
development and melanocytic differentiation. It is expressed in nearly all primary melanomas 
and its over-expression causes the formation of giant congenital naevi in mice8. Interestingly, 
many genes that are part of our invasive gene signature, including EGFR and TGF-ß, are up-
regulated 48 hours after SOX10 KD (Supplementary Fig. 29). This observation indicates that 
the gene regulatory network can be steered into a different attractor state simply by perturbing 
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one of the master regulators and is consistent with the ability in melanoma to switch from a 
proliferative to an invasive state through transcriptional reprogramming. And although no 
SOX10 ChIP-seq data are available in melanoma to date, our integrative genomics approach 
identified a high-confidence set of direct SOX10 candidate target genes, including known targets 
MITF and DCT and showing a large overlap with direct MITF target genes, thus indicating a 
SOX10-MITF feed-forward loop.  
 
Contrary to the proliferative state, the analysis of the invasive transcriptome puts forward AP-1 
and TEAD as strong candidates for key regulators, neither of which have been directly 
implicated in the melanoma invasive gene network before. However, both AP-1 and TEAD have 
been implicated in EMT, either separately or together, as illustrated by recent evidence 
supporting a direct interaction between YAP and the AP-1 family member FOS during EMT44 
Notably, in support of our findings on TEAD, two recent studies have attributed pro-invasive 
roles for YAP and TAZ in melanoma34. We find that AP-1 and TEAD share many of their targets 
indicating that these factors may act cooperatively to regulate gene expression. Consistently, 
independent public data from ENCODE, as well as our own predicted invasive enhancers 
support the hypothesis that AP-1 and TEAD binding sites often overlap at the same regulatory 
region. Note though that many of these predicted target regions are located at a considerable 
distance from potential target genes. This fact poses a challenge to associate differentially active 
regulatory regions with differentially expressed candidate target genes. Distal enhancers have 
been shown to be able to regulate their target genes even when located thousands of bp from the 
TSS, and with intermittent “bystander genes” present. By establishing correlations between 
enhancer and gene activity and performing 4C-seq, we have predicted and confirmed that for 
SOX9 these enhancers indeed interact at a long distance by enhancer-enhancer and/or enhancer-
promoter looping. Notably, the observed architecture of loops differs strongly between invasive 
and proliferative samples, elegantly explaining the differential expression of this target gene. 
This indicates that long-range chromatin interactions are dynamic and play a role in activating 
transcription. These results form compelling evidence for the role of the chromatin landscape in 
shaping the transcriptome underlying different cellular states.  
 
One of the consequences of this complex regulatory system is that up-regulation of genes 
involved in invasion, seems to correlate with an increased therapy resistance in patients. For 
instance, an increase in EGFR and a concomitant decrease in SOX10 expression have been 
linked to the development of resistance against BRAF inhibitors1. Here, we show for the first 
time that the invasive melanoma state is functionally dependent on TEADs, and that blocking the 
activity of this family of TFs increases the sensitivity of invasive cells to MAPK-targeted drugs. 
Based on these observations we propose that the intrinsic sensitivity of melanomas to MAPK 
pathway inhibitors is dictated by their transcriptional cell states, which are in turn controlled by 
specific master regulators.  
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In conclusion, our study shows that integrating existing data sets with carefully designed in vitro 
experiments is a valid approach to tackle a clinically relevant cancer issue. By investigating the 
information flow from the genome sequence, via the chromatin landscape to the transcriptome 
output we indeed gained insights into how gene regulatory networks instruct cells to adopt the 
phenotypically distinct invasive and proliferative melanoma states. Our results raise the 
possibility that intra-tumor heterogeneity and therapeutic sensitivity can be under the control of 
the cancer cell regulatory genome. 
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Methods 
 
Analysis of publicly available microarray data 
Two microarray platform gene expression compendia (Compendium A and Compendium B) 
were created from the publicly available gene expression datasets. Compendium A consisted of 
two datasets generated with Affymetrix Human Genome U133A Arrays totaling to 135 samples, 
while Compendium B consisted of 7 datasets generated with Affymetrix U133 PLUS 2.0 arrays 
and totaling to 263 samples (Supplementary Table 1). Raw intensities were downloaded from 
GEO, normalized with limma45 package and merged (per platform) with COMBAT batch effect 
removal procedure using the inSilicoDB46 package. For both of the datasets, non-negative matrix 
factorization (NMF) was performed in TMEV47 using all genes with an expression standard 
deviation above 1 (572 and 1868 genes, respectively) across all samples. Cluster specific gene 
rankings were obtained by contrasting the samples with the rest of the samples and signed -
log10(adjusted p-values) were used for ranking the genes. Differential expression analysis was 
performed with limma package in R/Bioconductor. The rankings were analyzed with GSEA48 
using the pre-ranked analysis option. The gene signatures that are used in the GSEA included 
known pathways from KEGG and REACTOME; functional terms from GO; curated gene 
signatures from msigdb (v4); and literature mined signatures (Widmer3, Cheng49, Hoek4, 
Messina50); in total comprising 10302 signatures.  
 
Analysis of TCGA/SKCM data  
The raw count matrix composed of 375 samples was downloaded from the Firehose (stddata, 
timestamp: 16_03_2014, cohort: SKCM). Non-negative matrix factorization (NMF) was 
performed using 501 genes that have expression standard deviation above 1 across all samples. 
Once the sample clusters were identified, the same procedures as above were implemented for 
generating cluster specific gene rankings and performing functional enrichment analysis. 
Differential expression analysis was done using R/Bioconductor DESeq251 package. Somatic 
mutation calls for 345 samples and significantly mutated genes list (Mutation Analysis (MutSig 
v2.0 and MutSigCV v0.9 merged result) were downloaded from Firehose (SKCM analyses, 
timestamp: 2014_06_12, doi:10.7908/C1668BVC). There were 343 samples that had both a 
cluster assignment in the NMF analysis and a somatic mutation called. These 343 samples were 
used to analyzing whether there was an association between mutation frequency and NMF 
cluster assignment using a Kruskal-Wallis rank sum test. Additionally, Fisher’s exact test was 
used to test the association between mutation status of significantly mutated genes with the NMF 
clusters. Bonferroni’s method was used to correct for multiple hypothesis testing. Illumina 
Infinium Human DNA Methylation 450 data file (platform code: HumanMethylation450) was 
downloaded from Firehose (SKCM, timestamp 16_03_2014). Two-sample t-test between the 
proliferative and invasive groups was performed to assess statistical significance of the 
methylated CpGs. This test yielded 1813 significantly methylated CpGs between the groups (α = 
1e-10). Predicted regulatory regions from the invasive and proliferative groups were intersected 
with the 450K array probes. Median methylation values were computed for the regulatory 
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regions with at least 2 CpG probes. Differentially methylated cis-regulatory modules were 
defined using a t-test with α = 0.05.  
 
GENIE3 
Co-expression networks from the expression datasets were generated using Genie324 on the same 
datasets as NMF analysis. The input list of TFs we used for GENIE3 (2245 factors) was 
compiled from the factor list from the TRANSFAC® Professional database combined with a list 
of factors from the Molecular Signatures Database (MSigDB) collection (v4). A threshold of 
0.007 was used to generate the final co-expression network.  
 
Meta-analysis  
Within each data set (TCGA, Compendium A, Compendium B and in-house RNAseq) invasive 
and proliferative gene rankings were generated by comparing invasive and proliferative samples 
to the rest of the samples. The rankings were then combined with order statistics, used previously 
for gene prioritization52,53. The gene meta-ranking for each state was subsequently analyzed with 
GSEA.   
 
Mosaic plots  
To generate mosaic plots we used GEDI13 (Gene Expression Dynamics Inspector) v2.1 on our 
gene expression and regulatory data to generate SOMs for each sample, which allowed to 
visualize the high number of genes/regions in maps of size 26x25 tiles, where each tile can 
include no or several similar genes/regions. Static analysis was used with default settings. For 
Figure 1d, row-median normalized expression values across 829 samples (135 Compendia A, 
263 Compendia B, 375 SKCM, 11 in-house and 45 short-term melanoma cultures6) were 
combined, and genes with expression standard deviation above 0.5 (1135 genes) were plotted 
with GEDI.  For Figure 3b, the regulatory regions having SD>=1 for H3K27ac and any signal 
for both H3K27me3 and FAIRE after data normalization were selected (the regions with 
H3K27m3 and FAIRE do not necessarily have SD>1). This yielded a set of 55919 regulatory 
regions with signal across 3 different regulatory data layers. The values were row-median 
centered within a dataset, then scaled across the datasets. 
 
Cell culture 
Cells were all kept at 37°C, with 5% CO2. The 10 primary melanoma cultures are all short-term 
cultures derived from patient biopsies and were described before14. Additionally, MM029 is a 
novel acquired short-term culture obtained under the conditions as the other cultures. All cultures 
were obtained with written consent from each subject and as part of a study for which ethical 
approval was granted. These cultures were maintained in Ham’s F1-0 nutrient mix (invitrogen) 
supplemented with 10% fetal bovine serum (Invitrogen), 4.8mM Ala-Gln (Sigma) and 100 µg/ml 
penicillin/streptomycin (Invitrogen). When performing KD experiments, antibiotics were omitted 
from the medium. SK-MEL-5 cells were purchased from ATCC and cultured in EMEM (gibco) 
supplemented with 10% FBS (Invitrogen) and 100 µg/ml penicillin/streptomycin (Invitrogen).  
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RNA-seq  
All 11 melanoma cultures were plated onto 15 cm plates and grown to ~85% confluence. 
Similarly, when performing KD experiments cells were plated into 6 well plates and grown to 
~85% confluence. Cells were then collected and prepared for RNA extraction according to the 
RNeasy protocol (Qiagen), yielding between 2 - 40 µg of total RNA per cell line. Quality checks 
were performed using the Bioanalyzer 1000 DNA chip (Agilent) after which libraries were 
constructed according to the Illumina® TruSeqTM RNA Sample preparation guide. Final libraries 
were pooled and sequenced on the HISeq 2000 (Illumina), generating between 15 - 30 million 
paired end or single end reads (TEAD KD).  
RNA-seq reads were mapped to the genome (Gencode v18) using TopHat2 2.0.9 with Bowtie2 
2.1.0 applying the --read-realign-edit-dist 0 option to enable combined mapping54. The sensitive-
local setting for Bowtie2 was used to correct for a high percentage of mismatches at the start of a 
read, prompting the removal of the first base pair for each read. Read counts per gene were 
obtained from the aligned reads using htseq-count command from the HTSeq framework55. The 
Bioconductor/R packages EDASeq , edgeR, and DESeq251 were used for normalization and 
differential gene expression analysis (Supplementary Data 1, 5).  
 
Gene signatures 
Using a cutoff of log2 fold change ≥ |1| and adjusted p-value ≤ 0.05 (R/Bioconductor package 
DESeq2_1.4.5), gene signatures of 643 and 772 genes were defines as invasive and proliferative 
signatures respectively. These cutoffs were confirmed by GSEA analyses using a ranking of all 
genes based on the signed -log10(adjusted p-value) of the differential expression contrasting 
invasive and proliferative cultures. Input sets used are the Hoek signatures (45 invasive and 52 
proliferative genes). Significant correlations (FDR<0.001) and a signature-derived leading edge 
provided a set of 660 proliferative and 499 invasive genes. These signatures are very comparable 
to the ones obtained using the aforementioned arbitrary cutoffs, and thus justify their usage. 
 
Variant/Mutation calling 
Single nucleotide variations (SNVs) and small insertion/deletions (INDELs) were called from 
the RNA-seq data with SAMTools v0.1.19+56. Variants observed in regions with less than 20 
reads and INDELs located in homopolymer stretches of >4bp were filtered out, as were 
polymorphisms matching the dbSNP138-common variants. The remaining variants were 
annotated with Variant Effect Predictor v2.757. The following terms were used for selecting the 
protein altering mutations: splice_donor_variant, splice_acceptor_variant, stop_gained, 
initiator_codon_variant, missense_variant, splice_region_variant, inframe_insertion, 
inframe_deletion, frameshift_variant.  
 
ChIP-Seq 
All 11 melanoma samples were grown to ~85% confluence per 15 cm dish. A total of 20 million 
cells per sample were was collected, yielding around 20 fractions of chromatin. ChIP samples 
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were prepared following the Magna ChIP-SeqTM preparation kit using at least 2 chromatin 
fractions and 2-2.5µg of antibody per fraction. Following antibodies were used for each ChIP: 
anti-histone H3 acetyl K27 antibody (ab4729, abcam); anti-trimethyl-Histone H3 (Lys27) 
antibody (07-499, Millipore); anti-MITF antibody (ab12039, abcam); anti-SOX10 antibody (sc-
17342, santa-cruz). Per sample, 5-30 ng of precipitated DNA or input was used to perform 
library preparation according to the Illumina® TruSeqTM DNA Sample preparation guide. In 
brief, the immunoprecipitated DNA was end-repaired, A-tailed, and ligated to diluted sequencing 
adapters (1/100). After PCR amplification (15-18 cycles) and bead purification (Agencourt 
AmpureXp, Analis), the libraries with fragment size of 300-500bp were sequenced using the 
HiSeq 2000 (Illumina).   
 
FAIRE-seq 
11 melanoma cultures were grown to ~85% confluence per 15 cm dish. A total of 10 million 
cells were collected per cell line, after which cells were fixed for 10 minutes with 4% 
formaldehyde and quenched (125mM Glycine; 0.01% Triton X-100 in PBS) for 10 minutes. 
Cells were then washed twice with PBS and pelleted in 2 ml PBS with protease inhibitor 
cocktail. Chromatin was collected subjecting the cells to three lysis steps, starting with 1 ml of 
lysis buffer 1 (50mM Hepes-KOH pH 7.5; 140 mM NaCl; 1 mM EDTA; 10% glycerol) at 4°C 
for 10 min and spun down at 1300g for 5 min. Secondly, 1ml of lysis buffer 2 was applied 
(10mM Tris-HCl pH 8.0; 200mM NaCl; 1 mM EDTA; 0.5 mM EGTA) and left to incubate for 
10 min. After another spin down 300 µl of buffer 3 (10mM Tris-HCl pH 8.0; 100mM NaCl; 1 
mM EDTA; 0.5 mM EGTA; 0.1% Na-deoxycholate) was added and cells were sonicated 
(Bioruptor UCD-200, Diagenode) for 12 cycles of 30 seconds pulses. Phenol/chloroform 
extraction was performed using Maxtract high density tubes (Qiagen) to separate the aqueous 
and organic phase. DNA was precipitated using Sodium acetate (0.3 M, pH 5.2), 20µg Glycogen 
and 95% ethanol. The pellet was re-suspended in 50 μl TE buffer and incubated at 37°C for 1 
hour with 1 μl RNAseA (10mg/ml). DNA was purified using the QiaQuick MinElute kit 
(Qiagen). Final libraries were prepared identical to ChIP-Seq libraries.  
 
Candidate regulatory regions 
Candidate regulatory regions in the human were defined using publicly available regulatory data: 
DHS from ENCODE58, General Binding Preference models59, CpG islands, proximal promoters, 
conserved non-coding sequences, ultra-conserved elements, regulatory elements from 
OregAnno60, VistaEnhancers61 and predicted cis-regulatory modules62 (Supplementary Table 
4). The UCSC liftover tool was used to convert genome coordinates to hg19 if needed. All these 
features were merged. In a first step, regions having an overlap of at least 20% or 80% with 
insulator elements in the genome or coding exons respectively were removed. Next, regions with 
an overlap smaller then 20% or 80% with insulators or exons are split and the regions containing 
the insulator or coding exons were removed. Remaining regions are then filtered based on size 
and regions < 30bp are removed. Finally, any resulting regions shorter than 1000 bp were 
extended if possible to 1000bp in a direction that prevents overlap with an insulator or exon. The 
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complete procedure of creating candidate regulatory regions yielded 1,223,024 regions 
(representing ~35% of the genome) with average size 818 bp, which can be found as a track in 
the Melanoma Track Hub (see Accession codes).  
 
Motif and track discovery  
We previously developed a tool for the Drosophila genome called i-cisTarget63 allowing the 
identification of the most enriched/correlated NGS tracks and motifs for a given set of genes or 
loci by an enrichment detection method. Here, we ported this framework to the human genome, 
starting from a set of predefined candidate regulatory regions. These regions were scored and 
ranked in the same way as described for the Drosophila version of i-cisTarget63, now using 1121 
human regulatory tracks with ChIP-seq data for 247 sequence-specific transcription factors 
across 43 different cell types and conditions. These datasets were mainly obtained from 
ENCODE database (999 tracks) but also include ChIP-seq data published by the Taipale lab (117 
tracks64; coordinates of peaks converted from hg18 to hg19 using the UCSC liftover tool), MITF 
ChIP-seq in the 501Mel melanoma cell line21 and 4 in-house tracks (ChIP-seq against p53 in 
MCF7 after Nutlin-3a stimulation and control65, and ChIP-seq against MITF in MM011 and 
MM031 from this study). For scoring the maximum score of the peaks was used (signalValue or 
fold_enrichment from encodePeak file format or MACS2 peaks respectively).  
For motif discovery, all 1.2 Mio regions are scored with a collection of 9,713 PWMs (motifs) 
from different resources65. PWM scoring is performed with Hidden Markov Models, one PWM 
at a time, across all 1.2Mio regions, and across all orthologous regions in ten other vertebrate 
species (orthologous regions determined by the UCSC liftover tool). Rankings across species are 
integrated using order statistics. A set of co-regulated input peaks is first mapped to the 1.2Mio 
regions, and for each feature (motif or track), the area under the cumulative recovery of these 
“foreground” regions is calculated (at 0.25% cutoff). The areas for all features are normalized 
using a Normalized Enrichment Score (AUC-µ/σ). Similar enriched motifs are clustered together 
using STAMP. The significance was computed using the hypergeometric test and Bonferroni’s 
method was used to correct for multiple hypothesis testing. 
 
Analysis of ChIP-seq and FAIRE-seq data 
ChIP-seq and FAIRE-seq reads were mapped to the genome (hg19-Gencode v18) using Bowtie2 
2.1.0. The sensitive-local setting for Bowtie2 was used to correct for a high percentage of 
mismatches at the start of a read, prompting the removal of the first five base pairs of each read. 
The coverage of candidate regulatory regions (described above) was computed using BEDTools. 
Subsequently, regularized log transformation and DESeq function from R/Bioconductor package 
DESeq251 (DESeq2_1.4.5) were used to detect differentially active regions between the 2 
invasive and 9 proliferative samples. On the H3K27Ac signal, applying threshold adjP ≤ 0.05 
and log2FC ≥ |1| lead to 13671 regions more active in invasive samples and 7146 regions more 
active in proliferative samples. These regions were then filtered using differential peaks called by 
MACS266 algorithm (q<0.05, nomodel), with the proliferative samples as treatment and invasive 
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samples as control. This supported differentially called regions resulting in final sets of 13453 
invasive and 6669 proliferative regions.  
MITF ChIP-seq peaks were called using MACS266 algorithm with default options. Peaks were 
called for each replicate independently, and only those with q-value below 0.05 were selected for 
further analysis (3907 for MM011 and 810 for MM031) and visualized in the Melanoma Track 
Hub (see Accession codes). Signal enrichment at each genomic loci was detected using the F-seq 
software67 (version 1.84) with default options and identified peaks were visualized (with the 
exception of MITF ChIP-seq) in the Melanoma Track Hub.  
 
Region-to-genes assignment 
To assign the differentially active regions to genes we tested several approaches. The most 
common is the assignment to the closest gene without considering gene expression. For this 
basic approach were used two different gene annotations, namely RefSeq and Gencode v18 
annotations. To obtain more accurate assignment we also applied more sophisticated approach 
considering differential gene expression between proliferative and invasive samples. The 
assignment was performed to the genes with log2FC>=|1| without considering significance 
(which corresponds to the gene set of 1936 proliferative and 1437 invasive gene). The genes that 
are not differentially expressed are ignored. We tested different parameters, namely distance 
(proximal & intronic with distance <=10kb from the gene, then the closest or all the genes in the 
distance of 10kb, 20kb, 100kb, 1Mb or 2Mb from the region), adjusted p-value of differential 
gene expression (0.05, 0.1, 1), correlation between H3K27ac peak and gene expression (positive 
or absolute values of 0, 0.1, 0.3, 0.5, 0.7). In order to constructing the gene regulatory network 
depicted in Figure 5b candidate target regions of the four transcription factors were assigned to 
genes:  
- that are within 1Mb distance from the region  
- that are expressed differentially in the invasive-proliferative contrast at the adjusted p-
value level of 0.1 and log2FC>=|1| 
- for which the expression correlates with the H3K27ac peak of the region with absolute 
correlation coefficient of 0.3 or more.  
For Figure 5c, the optimal parameters were selected based on the GSEA enrichment results for 
genes ranked according to GENIE3 scores of the corresponding factor (for SOX10, MITF and 
AP-1 targets). For TEAD target predictions, TAZ perturbation data25 was used (with gene 
ranking based on log2FC upon TAZ activation)  since TEAD-based GENIE3 ranking did not 
result in significant enrichment. 
 
Analysis of the publicly available perturbation data 
The raw data for SOX10 (GSE37059)8 and JUN and FRA1 (GSE46440)26 perturbations were 
downloaded from GEO. For the SOX10 (GSE37059) data analysis, the limma45 package was 
used for normalization and differential expression while JUN and FRA perturbation data were 
normalized with the aroma.affymetrix package and differential gene expression analysis were 
subsequently performed with the limma package in R/Bioconductor. TAZ perturbation data25 
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was kindly provided by Krishna Bhat and Brian Vaillant. Genes were ranked based on the log-
fold-change and this ranking was used for enrichment analysis using GSEA. MITF perturbation 
data was obtained from Supplementary Table 5 of Strub et al21. The genes were ranked based on 
the -log10 (p-value) for enrichment analysis.  
 
Circularized Chromosome Conformation Capture (4C) 
The protocol was adapted from Splinter et al.68. In brief, 10 million cells were collected for 
MM047 or MM011, treated with formaldehyde and cross-linked chromatin was digested with a 
primary 6-bp restriction enzyme, diluted and re-ligated to fuse the ends of DNA fragments. After 
cross-link removal by heating a second round of digestion, using a 4-bp restriction enzyme, was 
followed by ligation. Inverse PCR primers specific for the viewpoint were then used for 
amplifying captures ligated to that viewpoint. A total of 600 ng of template was used over 5 PCR 
reactions, pooled and then purified for next-generation sequencing using 2 columns per sample 
of the High Pure PCR Product Purification kit (Roche). Design of the primers was done as 
described previously68. Viewpoints selected are: viewpoint 2 in the promoter region of SOX9 
and viewpoint 1, located in a distal enhancer region 1Mb upstream of SOX9. The following 
restriction enzymes where selected for each viewpoint: EcoRI and DpnII for the Sox9 promoter 
and HindIII and DpnII for the distal enhancer region. The primers used during the protocol can 
be found in Supplementary Table 6. Sequenced reads were cleaned and mapped as described 
for RNA-seq with an additional removal of the primer sequences from each read. A publicly 
available bioinformatics software package r3Cseq69 was used to identify interaction-enriched 
regions per restriction enzyme fragment. Each 4C-seq sample was processed independently. 
Interactions with p-value <0.05 were considered significant. Interactions within 1 Mb around the 
viewpoint were visualized as domainogram plots. Note that the overlap of predicted interactions 
with the H3K27ac peaks (Fig. 6a) is not always exact due to the predefined restriction sites 
required for 4C-seq. 
 
qPCR 
The invasive melanoma cell lines were transfected with scramble siRNA, a pool of siRNAs 
against the four known TEADs or against one specific TEAD. Total RNA was harvested 72h or 
96h after transfection and extracted according to the RNeasy protocol. Reverse transcription was 
performed using the GoScript reverse transcription system (Promega). Alternatively RNA 
collected for qPCR on SOX10, MITF and EGFR was done by washing cells in ice-cold PBS, 
scraped and pelleted at 1500rmp for 5min at 4°C. Supernatant was discarded and the pellet 
resuspended in Qiazol (Qiagen). RNA was extracted with the miRNeasy mini kit (Qiagen). 
500ng of mRNA was converted to cDNA with the AB High Capacity cDNA Reverse 
Transcription Kit (Life Technologies). Real Time quantitative PCR reactions were run on 
LightCycler480 (Roche) in 384-well format, using SYBR-Green Fast Universal PCR Master Mix 
(Applied Biosystems). Melting curve analysis confirmed amplification of a single product while 
normalization was done with the most stable of three reference genes, assessed by GeNorm 
analysis. Normalized relative fold changes of at least three biological replicates were averaged 
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before performing a student’s t-test to determine significance levels. RT-qPCR primer sequences 
can be found in Supplementary Table 6. 
 
Knock-down experiments 
Cells were seeded at a density of 1 million cells per 6 cm plate or 100 000 cells per well of a 12 
well plate. Transfections using Lipofectamine RNAimax transfection reagens (Life 
Technologies) were performed for two consecutive days with 10nM of a pool of siRNAs against 
all 4 TEAD mRNAs or a non-targeting siControl pool (Dharmacon, D-001810-10). 
Alternatively, Knock down of single TEADs was achieved similarly by dual transfection using 
10nM of a pool of siRNAs against TEAD1 (Dharmacon, L-012603-00-0005) or a specific 
siRNA against TEAD2.  Analysis of the knock down efficiency and other assays were done 
between 72h - 120h after the first transfection. 
Matrigel invasion assay 
Matrigel basement membrane matrix gel (corning) was plated at 12.5 µg in 24-well transwell 
inserts (corning) one day in advance and let to solidify. Cells were collected, washed once with 
PBS and re-suspended in serum-free medium. 100,000 cells were plated per well and left to 
invade for 24h. Medium was removed and cells were stained using crystal violet (90% methanol 
(80%); 10% Formaldehyde; 5g/L crystal violet) for 10-20 minutes. After washing 3x with water, 
inserts were left to dry and any excess gel was removed from the inside of the inserts using a Q-
tip. Each condition was performed in duplicate. Five pictures per transwell were taken and 
analyzed for the presence of cells using imageJ. The average number of cells across at least three 
biological replicates was normalized and the significance was calculated using a student’s t-test.  
 
Cell viability assay  
Cells were plates at 10 000 cells/well in a 96-well plate. After 24h, cell viability was measured 
using the cellTiter-Glo luminescent cell viability assay (Promega). Each condition was 
performed in triplicates. Averages across three biological replicates were normalized and 
subjected to a student’s t-test for significance.  
 
IC50 determination 
Cells per plated at 10 000 or 3 000 cells/well in a 96-well plate depending on the length of the 
experiment. After 24h, a dilution series for BRAF (PLX4032, Selleck Chemicals) or MEK 
inhibitor (Pimasertib, Selleck Chemicals) was created ranging between 20 - 0.05 µM. 48h or 72h 
after stimulation, cell viability was measured. Measurements were normalized using cells treated 
with DMSO control as maximal viability. Each condition was performed in triplicates and final 
data points are the average of at least duplicate biological replicates. Curves were fitted and IC50 
calculated using a non-linear regression analysis in Graphpad Prism (version 6.0 for mac OS X, 
GraphPad Software, San Diego California USA, www.graphpad.com).  
 
Western blot 
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Cells were washed with ice-cold PBS and lysed in lysis buffer (50 mM HEPES; 150 mM NaCl; 
1 mM EGTA; 10 mM sodium pyrophosphate (pH 7.4)) containing 100 mM NaF, 10% glycerol, 
1.5 mM MgCl2, 1% Triton X-100, protease and phosphatase inhibitor (Roche). Extracts were 
incubated on ice for 20 min and spun down at 20800 g for 20 min. Protein concentration was 
determined using BCA protein assay reagent (Pierce). Equal amounts of protein from each 
sample were separated by electrophoresis through SDS-PAGE and transferred to PVDF 
membrane (Applichem). Membranes were blocked for 1 h at room temperature in Tris-buffered 
saline containing 0.1% Tween-20 (T-BST) and 5% nonfat dry milk. Membranes were incubated 
overnight at 4°C with primary antibody diluted in 5% nonfat dry milk in TBS-T. Proteins were 
detected using antibodies against TEAD1 (1/2000, BD Biosciences, 610922), β-actin (1/50000, 
Sigma, A2066), MITF (1/1000, Abcam, ab12039), SOX10 (1/1000, santa-cruz, sc-17342) and 
EGFR (1/1000, cell signaling tech, #4267S). Membranes were then washed and incubated for 1h 
at room temperature with peroxidase-conjugated secondary antibody (Thermo Scientific) or 2h 
with HRP-labeled secondary abs (Cell Signaling Technology). Protein bands were visualized 
using enhanced chemiluminescence as described by the manufacturer (Amersham, GE 
Healthcare). 
 
Analysis of the melanoma cell lines from CCLE  
Raw expression values for 39 cell lines were downloaded from GEO and processed using the 
limma 45 package in R/Bioconductor platform. IC50 values for PLX4720 and AZD6244 were 
obtained from the Supplementary Table 4 of Barretina et al 41. Pearson’s correlation coefficient 
was calculated between the IC50-value of the drug and the average expression of the TEAD-
activity signature (which is composed of 112 genes that are predicted as TEAD targets and also 
show log2FC>|1| with adjusted-p-value threshold of 0.05 in the TEAD-KD experiment ( 
Supplementary Data 6) using cor.test function in R.  
 
Drug inhibition assays 
200 000 cells were plated per 6-well. Cells were transfected to knock down all TEADs as 
described above. On day 3, 10 000 or 3 000 cells were seeded in 96 wells in triplicates. On Day 
four, variable concentrations ranging between 60 – 0.05 µM of BRAF inhibitor (PLX4032, 
Selleck Chemicals), MEK inhibitor (Pimasertib, Selleck Chemicals) were added. Alternatively, 
BRAF of MEK inhibitors were added at concentrations approximating the predicted IC50 value 
for each individual culture to measure potential additive effect of the TEAD KD. Cells treated 
with DMSO were used as a control and signify maximum cell viability. 48h or 72h after 
stimulation, cell viability was measured as described above. All measurements were done in 
triplicates. Final data points are averages of at least three biological replicates. IC50 shift curves 
were generated using the appropriate analysis protocol from Graphpad Prism.  
 
Accession codes 
The data generated for this study (Supplementary Table 5 and 7) has been deposited in NCBI's 
Gene Expression Omnibus70 and are accessible through GEO Series accession number 
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GSE60666 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE60666). This series 
contains 11 Paired-End RNA-seq data sets, 11 FAIRE-seq data sets, 11 ChIP-seq data sets for 
H3K27Ac, 11 ChIP-seq data sets for H3K27me3, 2 ChIP-seq data sets for MITF, 3 replicates 
single-end RNA-seq scrambled siRNA and 3 replicates TEAD siRNA. 
All processed data is furthermore available as a track hub in the UCSC Genome Browser using 
the following link: http://genome.ucsc.edu/cgi-
bin/hgTracks?db=hg19&hubUrl=http://ucsctracks.aertslab.org/papers/melanoma_paper/hub.txt 
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Figure Legends 
 
Figure 1 – Proliferative and invasive cellular states in melanoma biopsies and cultures.  
(a) Non-negative matrix factorization on TCGA-SKCM RNA-seq data results in three sample 
clusters. (b) Functional characteristics of two states revealed by gene set enrichment analysis 
(GSEA) on the invasive and the proliferative meta-rankings integrated across SKCM RNA-seq 
and two microarray compendia, using various sources of functional data (L) Literature; (R) 
Reactome; (KEGG) KEGG pathways; (GO) Gene Ontology; (T) TargetScan. (c) Expression 
heatmap for TCGA samples showing a core subset of invasive and proliferative gene signatures 
(the GSEA overlap between the Hoek signatures and our ranking). The samples are ranked 
according to MITF expression, and the expression levels of both MITF and ZEB1 are indicated 
on top of the heatmap. Below the heatmap are mosaic plots of several samples. Each mosaic 
shows the expression of all variable genes in a 25x26 grid, whereby each field contains one or 
more genes. Genes and clusters with similar expression profiles across the cohort are placed 
close to each other in the grid. The mosaics show a high similarity among the invasive samples, 
and a strong difference between invasive and proliferative samples. SKCM is RNA-seq data 
from TCGA; Hoek et al., is microarray data from melanoma cultures16; Compendium A and B 
are melanoma microarray data from GEO (see Supplementary Table 1 for accession numbers 
used).  
 
Figure 2 – Transcriptome and epigenome profiling in eleven melanoma cell cultures. RNA-
seq, FAIRE-seq, and ChIP-seq against H3K27Ac and H3K27me3 across ten short-passage 
melanoma cultures and one melanoma cell line SKMEL-5. The SOX10 gene shows high 
expression and its upstream regions contain high H3K27Ac and FAIRE but low H3K27me3 
signal in the nine proliferative (blue) samples. In the two invasive (orange) samples, there is no 
SOX10 expression, no H3K27Ac and FAIRE peaks but high H3K27me3 peaks. Upper panel 
shows one invasive sample (MM047) and one proliferative sample (MM011). Lower panels 
showing zoom in around the promoter region of SOX10 with tracks for all 11 samples for each of 
the 4 data types. Vertical axes represent normalized coverage for each data track. Arrows 
indicate regions of interest that are different between proliferative and invasive states. Other 
genes are illustrated in Supplementary Figures 4-5 and in the UCSC Genome Browser using 
our Melanoma Track Hub (see Methods). 
 
Figure 3 – Global changes in the chromatin landscape between proliferative and invasive 
states. (a) Multidimensional scaling using RNA-seq, H3K27ac and FAIRE-seq data reveals a 
clear separation of the invasive samples, with MM047 and MM099, from the proliferative. (b) 
Mosaic plots obtained by clustering 55919 regulatory regions show very similar chromatin 
profiles for MM047 and MM099, while the proliferative samples are characterized by higher 
heterogeneity. (c) Gene expression changes between invasive and proliferative samples correlate 
with changes in H3K27ac (for each gene from our signatures, the H3K27Ac differential peak 
called by MACS2 with the largest fold change in 20kb around the TSS is selected). Spearman’s 
rank correlation of coefficient is shown. (d) Inverse correlation between H3K27me3 peaks and 
gene expression changes. (e) Aggregation plots of the read coverage (y-axis) indicate that the 
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TSS (x-axis) of genes that are expressed higher in invasive samples (643 genes, left column) 
show higher FAIRE and H3K27ac signal but lower H3K27me3 signal in the same invasive 
(orange) samples than in the proliferative samples. Vice versa, the TSS of genes higher 
expressed in the proliferative samples (772 genes, right column) show higher activating signals 
in the proliferative samples, and higher repressive signal in the two invasive samples. (f) 
Concordance between chromatin landscape in vitro and in vivo, where in vivo hypermethylated 
regions in the invasive samples from TCGA data show high activity (H3K27ac) in proliferative 
in vitro cultures (nine blue curves), but no activity in the invasive cultures (two orange curves).  
 
Figure 4 – Enhancer signatures are enriched for transcription factor motifs and ChIP-seq 
tracks. (a) The proliferative enhancer signature (6669 regions) is most strongly enriched for 
SOX10 motifs (a SOX dimer motif is most significant), and E-box motifs (the second best 
scoring motif cluster, where the most significant E-box motif is ranked ninth after eight SOX10-
like motifs). (b) The E-box predicted enhancers are correlated with publicly available MITF 
ChIP-seq data (against HA-tagged MITF) in a proliferative melanoma culture. (c) The same 
public ChIP-seq data (MITF_HA) and in-house ChIP-seq data against endogenous MITF in two 
proliferative cultures (MM011 and MM031) confirm that SOX10 is a MITF target gene through 
the predicted upstream enhancer (arrowhead). MITF predicted binding sites (MITF_M) inside 
H3K27Ac peaks (blue peaks in proliferative samples) ~30kb upstream of SOX10 MITF overlap 
with MITF_HA and MITF ChIP-seq peaks. (d) The invasive enhancer signature (13453 regions) 
is most strongly enriched for AP-1 motifs (best-scoring motif cluster) and TEAD motifs (the 
second best scoring motif cluster) (Supplementary Fig. 15). (e) The predicted AP-1 enhancers 
are tested against all ENCODE ChIP-seq data and are correlated most strongly with ChIP-seq 
peaks of AP-1 complex members such as FOSL2 and JUND, derived from a neuroblastoma cell 
line (SK-N-SH) (ranked first out of 1121 tested ChIP-seq data sets). Likewise, TEAD predicted 
target enhancers are most strongly correlated with TEAD4 ChIP-seq in a neuroblastoma (SK-N-
SH) and lung cancer (A549) cell line.  
 
Figure 5 – Mapping gene regulatory networks from the enhancer signatures. (a) Cartoon 
showing the assignment of regions to genes. Each enhancer from either the invasive or 
proliferative enhancer signature is associated (red arches) with zero, one or more candidate target 
genes using various parameter settings, allowing very distal interactions up to 10kb, 100kb, 1Mb, 
or 2Mb from the TSS, with or without filtering for target genes having corresponding gene 
expression data. (b) Predicted invasive (right) and proliferative (left) networks showing high 
overlap between AP-1 and TEAD targets in the invasive network, and high overlap between 
MITF and SOX10 targets in the proliferative network. Region-to-gene association parameters 
used for this network are [d=1Mb; ge=0.1; corr=0.3] (see Methods). (c) Network validation 
using Gene Set Enrichment Analysis (GSEA) showing that predicted target genes for SOX10, 
AP-1, TEAD and MITF are functional targets based on co-expression (GENIE3 based co-
expression network on TCGA RNA-seq) and publicly available perturbation data for each factor 
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(see Methods). All shown enrichments are significant with FDR<0.0001 (except results for 
MITF KD where the shown enrichment are significant with FDR=0.0004 and FDR=0.0038). 
Target genes predicted by distal assignments (red curves) have more accurate predictions than 
assignments based on the closest genes (grey curves). Optimal region-to-gene association 
parameters used for the gene sets represented by red curves are: SOX10 [d=100kb & closest, 
ge=0.05, corr=0.1], MITF [d=2Mb, ge=0.05, corr=0.3], AP-1 [d=20kb, ge=1, corr=0.1], TEAD 
[d=100kb & closest, ge=1, corr=0.1 & abs]. 
 
 
Figure 6 – Long-range enhancer-promoter interactions at the SOX9 locus. (a) View of a 2 
Mb region around SOX9 showing 8 clusters of predicted AP-1 and TEAD enhancers that are 
specifically active in the invasive state, as reflected by the H3K27ac peaks present for MM047 
(orange) and absent in MM011 (blue). Different tracks show the motifs (AP1_M, TEAD_M) or 
ChIP-seq tracks (AP1_T, TEAD_T) detected for AP-1 and TEAD within these clusters. Arcs 
indicate correlations between the H3K27Ac profile (vector of 11 peak values) of distal enhancers 
and the expression profile (vector of 11 expression values) of SOX9. Viewpoint 1 and 2 indicate 
the selected anchor points for 4C interaction analysis. (b) 4C-seq performed in an invasive 
(MM047) and a proliferative culture (MM011) showing chromatin interactions with viewpoint 1, 
a region 1 Mb upstream of SOX9 TSS. This enhancer interacts with other distal enhancers and 
with the SOX9 promoter, only in the invasive sample. I-RR represents invasive regulatory 
regions, while TEAD4 and JUND represent tracks from publicly available ENCODE ChIP-seq 
data on SKSH cell line. The domainograms show the identified interactions after a window-
based analysis (from 2 to 25kb). Color gradients represent the interaction signal strength, x-axis 
represents the analysis window sizes, and the arcs below represent significant interactions at p-
value<0.05 threshold. (c) 4C-seq performed in an invasive (MM047) and a proliferative culture 
(MM011) showing chromatin interactions with viewpoint 2, the promoter of SOX9. The SOX9 
promoter interacts mostly with upstream enhancers.   
 
Figure 7 – TEAD as a master regulator for the invasive phenotype. (a) Simultaneous knock-
down of all 4 TEADs causes down-regulation of SOX9, SERPINE1 and EPHA2 expression in 
the invasive cultures as measured by qPCR. Measurements were normalized against the non-
target control within each culture and are averaged across at least three biological replicates. 
Error bars represent standard error of the mean, (asterisk = pval < 0.05). p-values were 
determined using student’s t-test (b) Selection of genes highly expressed in the invasive state and 
down-regulated upon TEAD knock down categorized into several functional groups relevant to 
the invasive phenotype (see Supplementary Data 3 for the entire list of annotated TEAD 
targets). Additionally, expression information of TCGA and CCLE data for each gene is 
provided. (c) Significant overlap of genes predicted as TEAD targets (grey) with genes assigned 
to the invasive signature (yellow; hypergeometric p-value = 5.83E-11) or with genes down-
regulated upon TEAD knock down (pink; hypergeometric p-value = 1.37E-23). (d) GSEA with 
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genes ranked according to their differential expression upon TEAD knock down show a strong 
enrichment of predicted TEAD targets amongst the down-regulated genes. (e) Images showing 
the reduced invasive capacity of MM047 and MM099 upon knock down of the TEADs (all 
images were made at magnification x20, scale bar = 0.2 mm).  (f) Knock-down of all 4 TEADs 
using a siRNA pool leads to a significant (p-value<0.05) reduction of the invasive capacity 
compared to a non-target control siRNA for all three invasive cultures. Results are averaged 
across at least 3 biological replicates. (g) Cell viability upon knock down of all 4 TEADs 
decreases significantly. P-values were determined using student’s t-test and the error bars 
represent standard error of the mean.  
 
Figure 8 – The role of the TEADs in drug resistance of the invasive melanoma state. (a) 
Analysis of CCLE data (n=39) shows a significant difference of IC50 values for both the BRAF 
and MEK inhibitors (PXL4032 and AZD6244), where cell lines with a high TEAD signature 
(top 25%) are more resistant compared to the other cell lines. (b) IC50 curves showing a strong 
resistance of invasive cultures (MM029, MM047 and MM099, orange shades) for both BRAF 
and MEK inhibitor (PLX4032 and Pimasertib) compared to two proliferative cultures (MM074 
and MM034, blue shades) both at 48h and 72h of exposure. MM047 data was not incorporated in 
BRAF related plots since this culture does not harbor the V600E BRAF mutation. (c) IC50 shifts 
indicating a sensitization of the invasive lines for the MEK inhibitor measured at 48 and 72h of 
treatment when treated with siRNAs against all four TEADs.  
All error bars represent standard error of the mean and are the result of at least three biological 
replicates. P-values were determined using student’s t-test. 








